HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

valanafusp alpha

a genetically engineered fusion protein of human iduronidase and a chimeric monoclonal antibody against the human insulin receptor

Also Known As:

AGT-181

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Boado, Ruben J: 3 articles (04/2018 - 10/2009)
2.	Pardridge, William M: 3 articles (04/2018 - 10/2009)
3.	Giugliani, Roberto: 2 articles (04/2018 - 01/2018)
4.	Schmidt, Mathias: 2 articles (04/2018 - 01/2018)
5.	Chen, Steven: 1 article (01/2018)
6.	Corte, Amauri Dalla: 1 article (01/2018)
7.	Donis, Karina Carvalho: 1 article (01/2018)
8.	Giugliani, Luciana: 1 article (01/2018)
9.	Nestrasil, Igor: 1 article (01/2018)
10.	Nguyen, Carol: 1 article (01/2018)

Related Diseases

1.	Cognitive Dysfunction 01/01/2018 - "We report the results of a 52-week clinical trial on the safety and efficacy of valanafusp alpha in pediatric MPSI patients with cognitive impairment. "
2.	Mucopolysaccharidosis I (Hurler Syndrome) 10/26/2009 - "The safety pharmacology studies provide the basis for future drug development of AGT-181 as a new therapeutic approach to treatment of the brain in Hurler's syndrome." 01/01/2018 - "Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial." 04/01/2018 - "Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I."

Related Drugs and Biologics

1.	Insulin Receptor
2.	Proteins (Proteins, Gene)
3.	Iduronidase (alpha-L-Iduronidase)